Chemical Sourcing Glossary: Terms Buyers Need

A chemical sourcing glossary is only useful if it is organized the way people actually learn. Alphabetical glossaries are reference tools for readers who already know the field — you look up the one word you forgot. Buyers new to chemical procurement have a different problem: they do not know which words they are missing, and the words they need most sit next to each other conceptually while being scattered across the alphabet.

So this one is arranged by theme. Seven groups, roughly 110 terms, each defined in two to four sentences that stand alone. Where a term changes a purchasing decision, there is a buyer note attached. The final section covers six pairs of terms that get conflated constantly — that section is the one worth bookmarking, because those confusions are where money actually leaks.

For an alphabetical lookup of the most common fifty terms, our chemical procurement glossary is the companion to this post. Use that one when you know the word; use this one when you do not know what you are missing.

Organization Types: Who You Are Actually Buying From

The acronyms describing chemical service providers overlap heavily, and vendors use them loosely in their own marketing. The distinction that matters is what the organization delivers: knowledge, material, or both.

CRO (Contract Research Organization). An organization that performs research services under contract — route scouting, medicinal chemistry, analytical method development, structure-activity studies, milligram to gram quantities of novel compounds. A CRO’s deliverable is primarily knowledge, with material as the physical evidence of it. CROs are generally not set up for repeat commercial manufacture and usually do not hold GMP registration for the compounds they make in discovery work. Buyer note: pay a CRO for problem-solving, not for kilograms. If you find yourself reordering the same compound from a CRO for the third time, you have outgrown the relationship and should be talking to a manufacturer. Our CRO buyer’s guide covers selection criteria in detail.

CDMO (Contract Development and Manufacturing Organization). An organization that both develops a manufacturing process and executes it at scale, typically under GMP. The development half covers process optimization, impurity control and scale-up; the manufacturing half covers routine commercial production, batch release and regulatory support. A CDMO’s deliverable is registered, releasable material made by a process it owns and can defend to an inspector. Buyer note: CDMO engagements carry a technology transfer cost that CRO engagements do not. Budget for it, and budget for the fact that transferring away later costs the same again.

CMO (Contract Manufacturing Organization). A manufacturer that executes a process it did not develop. You bring the process; they run it. The distinction from CDMO is the absence of the development function — a pure CMO is a set of hands and vessels operating under a quality system, not a source of process improvement. Many organizations that call themselves CMOs will in fact do development work, and many CDMOs will run pure toll manufacturing. Ask what is actually being sold.

CRDMO (Contract Research, Development and Manufacturing Organization). The full-span version: discovery research through commercial manufacture in one organization. The appeal is a single relationship from hit identification to launch with no technology transfers. The risk is concentration — the same organization owns your chemistry knowledge, your process and your supply, which is exactly the single-source position that our pharmaceutical supply chain de-risking framework exists to help you avoid.

API manufacturer. A facility that produces active pharmaceutical ingredients — the biologically active component of a drug product. API manufacture is a distinct regulatory category with its own inspection regime, and an API facility is registered with health authorities in a way an intermediate manufacturer need not be. Buyer note: a supplier making your intermediate is not automatically capable of making your API, even if the chemistry is similar. The gap is regulatory, not synthetic.

Distributor versus manufacturer. A manufacturer synthesizes material in a facility it controls and can produce the batch record. A distributor purchases finished material and resells it, sometimes repackaged under its own label and its own certificate of analysis. Both are legitimate; they solve different problems. A distributor gives you fast access to small quantities of thousands of compounds. A manufacturer gives you traceability to a specific process, the ability to scale, and someone to call when a lot fails. Buyer note: this distinction is the single most under-asked question in early sourcing. If the answer is a distributor, ask who actually made the material and whether that relationship is durable.

Virtual company. A pharmaceutical or biotech company that owns intellectual property and program direction but outsources essentially all laboratory and manufacturing execution. Virtual companies are heavy users of CROs and CDMOs by design, and their procurement function carries unusual weight, because the supply chain is the operating capability. Buyer note: virtual companies should over-invest in documentation from day one. When you have no internal laboratory, the supplier’s records are your records.

Material Grades and Quality Levels

Grade language describes documented evidence, not chemistry. Two materials of identical purity can carry different grades because different amounts of testing and record-keeping stand behind them.

Research grade. Material suitable for laboratory research, with a certificate of analysis showing identity and purity but no quality-system commitment behind it. Specifications are typically supplier-defined rather than compendial. The vast majority of catalog building blocks sold for discovery chemistry are research grade.

Technical grade. Material of commercial purity, usually below research grade, sold for industrial use where trace impurities do not affect the application. Purity is often stated as a minimum with wide tolerance and few impurities individually specified. Cheap, appropriate for process development trials, inappropriate for anything with an analytical specification attached.

ACS reagent grade. Material meeting the specifications published by the American Chemical Society in Reagent Chemicals. This is a genuine compendial standard with defined test methods and limits, not a marketing term. It matters most for common laboratory reagents and solvents where the ACS monograph is the accepted benchmark.

USP / EP / JP grade. Material meeting the monograph in the United States Pharmacopeia, European Pharmacopoeia or Japanese Pharmacopoeia respectively. A pharmacopeial monograph specifies identity tests, assay limits, specific impurity limits and the analytical methods to be used. Buyer note: pharmacopeial grade is a testing claim, not a manufacturing claim. USP grade material is not automatically GMP material, and GMP material is not automatically USP grade. If you need both, specify both.

Pharmacopeial. The adjective covering any of the above — material tested against and conforming to an official pharmacopeia monograph. When a supplier says “pharmacopeial grade” without naming which pharmacopeia, ask, because the monographs differ.

GMP (Good Manufacturing Practice). A quality system standard governing how material is made rather than what it contains. GMP requires documented procedures, batch records, qualified equipment, validated processes, released raw materials, trained personnel, change control, deviation handling and a quality unit that is organizationally independent of production. The standard for active pharmaceutical ingredients is ICH Q7.

cGMP (current Good Manufacturing Practice). The same concept with the word “current” doing real work: the standard is what regulators expect today, not what was acceptable when the facility was built. The “c” is the reason a facility passing inspection in 2015 can fail in 2027 with no change in its own practices.

GLP (Good Laboratory Practice). A quality system for non-clinical safety studies — toxicology, pharmacology, environmental fate. GLP governs study conduct, data integrity, archival and quality assurance audit of studies. It is not a manufacturing standard and it is not an analytical testing standard for release. Buyer note: GLP and GMP are not interchangeable and not a hierarchy. A GLP-compliant toxicology laboratory cannot release a GMP API batch, and a GMP plant cannot run a GLP study.

Non-GMP. Material made outside a GMP quality system. Perfectly appropriate for discovery, process development, method development, stability screening and toxicology supply in many cases. Substantially cheaper and faster than GMP material — typically a fraction of the cost and a fraction of the lead time. Our full comparison is in GMP versus non-GMP chemical manufacturing.

GMP-like. A term with no regulatory meaning. It generally signals a facility applying some GMP practices — batch records, controlled raw materials — without a full quality system, an independent quality unit or regulatory registration. Buyer note: “GMP-like” is not a grade. If a supplier uses the phrase, ask specifically which elements of the quality system are in place and which are not, in writing. The answer is usually informative and occasionally alarming.

Regulatory and Filing Terms

These terms describe how material relates to a regulatory submission. Getting them wrong means either over-buying documentation you do not need or discovering mid-program that you cannot file with the material you have.

Term	What it is	When a buyer meets it
API	Active pharmaceutical ingredient — the biologically active substance	Sourcing the drug substance itself
Drug substance	Regulatory synonym for API used in ICH and FDA documents	Reading filings and guidelines
Drug product	The finished dosage form: tablet, capsule, injectable, patch	Formulation and fill-finish sourcing
IND	Investigational New Drug application — permission to begin human trials in the US	First GMP campaign
NDA	New Drug Application — approval request for a novel drug	Commercial supply qualification
ANDA	Abbreviated New Drug Application — generic drug approval	Generic API sourcing
DMF (Type II)	Drug Master File covering drug substance, intermediates and their manufacture	Supplier holds it; you reference it
CEP	Certificate of Suitability to the European Pharmacopoeia	European filings
RSM	Registered starting material — where GMP begins in the route	Route and cost negotiation

API (active pharmaceutical ingredient). The substance in a medicine intended to have a therapeutic effect. Everything else in the dosage form is excipient. The API is the most heavily regulated single input in a pharmaceutical supply chain.

Drug substance. The regulatory term for the same thing. ICH guidelines and FDA guidance documents generally say “drug substance”; industry says “API”. They mean the same material.

Drug product. The finished dosage form administered to the patient. A different manufacturing discipline entirely — formulation, blending, compression, sterile fill — usually done at a different facility from the API.

IND (Investigational New Drug). The US application that permits human clinical study of a new molecule. The chemistry, manufacturing and controls section of an IND is where your sourcing decisions become regulatory commitments. See IND-enabling chemistry for what that entails.

NDA and ANDA. New Drug Application covers a novel product; Abbreviated New Drug Application covers a generic referencing an approved product. ANDA sourcing is unusually price-sensitive and unusually documentation-sensitive at the same time, because margins are thin and the bioequivalence case rests on material quality.

DMF Type II. A Drug Master File is a confidential submission to the FDA describing a facility, process, material or component. Type II covers drug substances, intermediates and the materials used in their preparation. A supplier holding a DMF lets you reference their proprietary process in your filing without seeing it. Buyer note: ask for the DMF number and a letter of authorization. A supplier who says they “have a DMF” but cannot produce a number and an LoA does not have one you can use.

CEP (Certificate of Suitability). Issued by the European Directorate for the Quality of Medicines, certifying that a substance made by a specified process is adequately controlled by the relevant European Pharmacopoeia monograph. Functionally the European counterpart to referencing a DMF, and often faster to work with.

Registered starting material (RSM). The defined point in a synthetic route at which GMP controls begin and from which the material appears in the regulatory filing. Steps upstream of the RSM can run non-GMP at lower cost; steps from the RSM forward are GMP. Buyer note: the position of the RSM is negotiated with the regulator, and it is one of the largest single levers on cost of goods. An RSM placed one step later can remove an entire GMP step from your supply chain.

ICH (International Council for Harmonisation). The body that develops harmonized technical guidelines for pharmaceutical development and registration across the US, EU, Japan and beyond. ICH guidelines are not law, but regulators expect conformance and will ask why if you deviate.

FDA Form 483. The list of observations an FDA investigator issues at the close of a facility inspection, documenting conditions that in the investigator’s judgment may violate regulations. A 483 is not a finding of violation and not a legal action. Buyer note: a 483 with two minor observations is normal. Read the observations, not the count. Repeat observations across inspections are the real signal.

EIR (Establishment Inspection Report). The full narrative report the FDA writes after an inspection, including the classification of the outcome. More informative than a 483 and harder to obtain, but worth requesting from a supplier during qualification.

Warning letter. A formal FDA communication stating that the agency has found significant violations and requiring corrective action. A materially more serious signal than a 483. The FDA warning letter database is public and searchable, and should be part of every supplier screen.

Establishment registration. The requirement that facilities manufacturing drugs for the US market register with the FDA and list their products. Registration is a factual status, not an approval or an endorsement — it means the agency knows the facility exists and can inspect it.

DEA registration. Required to handle controlled substances and, in many cases, listed chemicals that can be used in their manufacture. DEA-registered capability is scarce, adds lead time to every order, and constrains which suppliers can quote at all. Buyer note: identify controlled or listed status at the specification stage, not at the quotation stage. It changes the supplier universe entirely.

TSCA (Toxic Substances Control Act). The US statute governing industrial chemicals, administered by the EPA. Substances manufactured in or imported into the US for commercial purposes must be on the TSCA Inventory or covered by an exemption — research and development quantities have one, commercial quantities generally do not. Our procurement-focused treatment is in navigating TSCA compliance.

FIFRA (Federal Insecticide, Fungicide, and Rodenticide Act). The US statute governing pesticide registration and labeling. Relevant to agrochemical intermediates and to any compound whose eventual use is pesticidal, where registration obligations attach downstream of your purchase.

REACH. The European Union regulation on Registration, Evaluation, Authorisation and Restriction of Chemicals. Substances imported into or manufactured in the EU above one tonne per year require registration. Buyer note: REACH obligations sit with the EU importer. If you buy DDP from a non-EU supplier into an EU site, confirm in writing who is the importer of record and who holds the registration.

ICH Guideline Shorthand Buyers Actually Encounter

Suppliers cite ICH numbers as shorthand and assume you know them. These nine cover most of what appears in commercial correspondence.

Guideline	Subject	Why a buyer cares
Q1A	Stability testing of new drug substances and products	Sets retest date and storage claims
Q2	Validation of analytical procedures	Defines what “validated method” means
Q3A / Q3B	Impurities in new drug substances / products	Reporting, identification and qualification thresholds
Q3C	Residual solvents	Class 1, 2, 3 solvent limits
Q3D	Elemental impurities	Risk-based metal limits, catalyst residues
Q7	GMP for active pharmaceutical ingredients	The GMP standard for APIs
Q11	Development and manufacture of drug substances	Route justification and RSM selection
Q13	Continuous manufacturing	Flow and continuous process expectations
M7	Mutagenic impurities	Genotoxic impurity control, DNA-reactive alerts

Q3A and Q3B — impurities. Q3A covers impurities in new drug substances, Q3B in new drug products. They set the thresholds at which an impurity must be reported, identified and toxicologically qualified, expressed as a percentage of the drug substance and keyed to maximum daily dose. Buyer note: these thresholds are why a supplier’s “99.5 percent pure” may still be unacceptable. A single 0.3 percent unknown can require identification work costing more than the material.

Q3C — residual solvents. Classifies solvents into Class 1 (avoid — benzene, carbon tetrachloride and similar), Class 2 (limit — methanol, dichloromethane, toluene and others), and Class 3 (low toxic potential, limited by GMP practice, generally 5000 ppm). Buyer note: if your supplier’s route uses a Class 1 solvent anywhere, that is a route problem, not a purification problem. Ask early.

Q3D — elemental impurities. Establishes permitted daily exposures for elemental impurities grouped by toxicity and route of administration, and requires a risk assessment rather than blanket testing. Palladium, platinum, nickel, copper and ruthenium matter most in synthesis because they arrive as catalyst residues. Our detailed treatment is in elemental impurities under ICH Q3D.

Q7 — GMP for APIs. The operative GMP standard for active pharmaceutical ingredients and their intermediates. It is also where the concept of the starting material and the point of GMP entry is set out. When a supplier says “we are Q7 compliant”, the useful follow-up is which sections, verified by whom, and when they were last audited against it.

Q11 — drug substance development and manufacture. Covers how you justify your synthetic route, select and justify your starting materials, and describe your control strategy. Q11 is the guideline that governs the RSM negotiation described above.

Q13 — continuous manufacturing. Sets expectations for continuous and flow processes, including material traceability, state of control, and batch definition when there is no discrete batch. Increasingly relevant as flow chemistry moves from a laboratory technique to a manufacturing one.

M7 — mutagenic impurities. Governs assessment and control of DNA-reactive impurities, including the well-known nitrosamine and alkyl halide classes. M7 uses a threshold of toxicological concern approach and structural alerts. Buyer note: alkylating agents, sulfonate esters and aryl amines in a route trigger M7 work. Ask what the supplier’s control strategy is before you commit to the route, not after.

Q1A — stability. Defines the storage conditions, time points and testing required to establish shelf life or retest date. This is where a supplier’s retest date on a certificate of analysis comes from, and why “we have always stored it at room temperature” is not a stability claim.

Q2 — analytical validation. Defines the characteristics a validated analytical procedure must demonstrate: specificity, linearity, range, accuracy, precision, detection limit, quantitation limit and robustness. When two suppliers report different results on the same lot, the difference is usually in one of these eight.

Analytical Terms

Analytical vocabulary is where buyers most often accept a number without knowing what produced it. These are the terms that appear on a certificate of analysis or a quotation for testing.

COA (Certificate of Analysis). A document from the manufacturer stating the test results for a specific lot against a specification. A real COA names the lot, the test methods, the specification limits, the results, the date and a responsible signatory. A COA that lists only results with no methods and no limits is a sales document.

COC (Certificate of Conformance). A statement that material conforms to a specification, without necessarily reporting individual test results. Weaker than a COA. Buyer note: if you asked for a COA and received a COC, you did not get what you asked for. Say so before you accept the lot.

HPLC (High-Performance Liquid Chromatography). The workhorse separation technique for non-volatile organic compounds. Separates components of a mixture on a packed column under pressure, detected typically by ultraviolet absorbance. Most purity numbers on a COA for a pharmaceutical intermediate come from HPLC. Method development for a new compound is a real project — see HPLC method development.

UPLC / UHPLC (Ultra-High-Performance Liquid Chromatography). HPLC run at higher pressure with sub-two-micron particles, giving faster runs and sharper peaks. Results are generally comparable to HPLC but not automatically transferable — a method must be converted and revalidated, not simply run on the newer instrument.

GC (Gas Chromatography). Separation of volatile and thermally stable compounds in the gas phase. The standard technique for residual solvents and for volatile impurities that HPLC does not see well.

GC-MS and LC-MS. Gas or liquid chromatography coupled to mass spectrometry, giving both separation and molecular weight information. These are identification techniques as much as quantitation techniques — they tell you what the unknown peak probably is, which HPLC with UV detection cannot.

NMR (Nuclear Magnetic Resonance). Spectroscopy that reports the magnetic environment of nuclei, most commonly proton and carbon-13. NMR is the primary structural confirmation technique in synthetic chemistry and can also serve as a quantitative assay method when run against an internal standard (qNMR). Buyer note: an NMR spectrum in the data package is the cheapest insurance against receiving the wrong compound. Ask for the raw file, not a picture of it.

ICP-OES and ICP-MS. Inductively coupled plasma optical emission spectroscopy and mass spectrometry — the two techniques used to quantify metals. ICP-OES covers the parts-per-million range comfortably; ICP-MS reaches parts per billion. These are the methods behind an ICH Q3D elemental impurity result.

Karl Fischer titration. The standard method for water content, based on a specific reaction with iodine. Reported as percent water by weight. Matters for assay reconciliation, for stability, and for any moisture-sensitive downstream reaction.

DSC (Differential Scanning Calorimetry). Measures heat flow into or out of a sample as temperature changes, revealing melting points, polymorphic transitions, glass transitions and crystallinity. The primary tool for detecting a form change between lots.

TGA (Thermogravimetric Analysis). Measures mass loss as a function of temperature, distinguishing solvent or water loss from decomposition. Run alongside DSC, it tells you whether a thermal event is a phase transition or a loss of volatiles.

XRPD (X-Ray Powder Diffraction). Identifies crystalline form by diffraction pattern. The definitive method for confirming that this lot is the same polymorph as the last lot. Buyer note: for any solid API or crystalline intermediate whose form matters downstream, XRPD belongs on the specification. It is inexpensive relative to discovering a form change during formulation.

LOD and LOQ. Limit of detection is the lowest amount distinguishable from noise; limit of quantitation is the lowest amount measurable with acceptable precision. A “not detected” result is meaningless without the LOD attached. Buyer note: always require the LOD or LOQ next to any “not detected” or “below limit” entry on a COA.

Assay versus purity. Assay is the quantity of the named substance present, determined against a reference standard. Purity is the proportion of the sample that is not something else, usually chromatographic area percent. They are different measurements answering different questions, and the gap between them is discussed in full in the final section.

Area percent. The proportion of total integrated chromatographic peak area attributable to a given peak. It assumes every component responds equally to the detector, which is rarely true, and it cannot see anything that does not elute or does not absorb. Useful, ubiquitous, and routinely over-interpreted.

ee (enantiomeric excess). For a chiral compound, the excess of one enantiomer over the other, expressed as a percentage — 98 percent ee means 99 percent of one enantiomer and 1 percent of the other. Measured by chiral chromatography or chiral NMR methods. Buyer note: ee is method-dependent. Two suppliers reporting 99 percent ee on different columns are not necessarily making equivalent material. Align the method before comparing lots. See chiral resolution versus asymmetric synthesis for the routes that generate it.

de (diastereomeric excess). The analogous measure for diastereomers — relevant when a molecule has two or more stereocenters and the relative configuration is what varies.

Specific rotation. The rotation of plane-polarized light by a solution of a chiral compound at defined concentration, path length, temperature and wavelength. A classical identity and purity check. Weaker than chiral chromatography for quantifying ee, but cheap and still specified in many pharmacopeial monographs.

Residual solvents. Solvents remaining in the isolated product from synthesis or purification, controlled under ICH Q3C and measured by GC, usually headspace GC. A frequent cause of the gap between area-percent purity and assay.

Water content. Free and bound water in a sample, typically by Karl Fischer. The other frequent cause of that gap, and the reason hygroscopic materials should be assayed as received rather than on a dried basis unless the specification says otherwise.

Method validation. The formal demonstration, per ICH Q2, that an analytical procedure is fit for its purpose across specificity, linearity, range, accuracy, precision, detection and quantitation limits, and robustness. Validation is done once, by the originating laboratory, and documented in a report.

Method transfer. The process of demonstrating that a second laboratory can run a validated method and obtain equivalent results, usually by comparative testing on shared samples against predefined acceptance criteria. Buyer note: method transfer is the most commonly underestimated line item in second-source qualification. Budget four to eight weeks and dedicated analytical time, and start it before the sample arrives, not after. Our analytical services group runs transfers of this kind routinely.

Chemistry and Process Terms

These terms describe the material and the process that made it. Buyers who understand them write better specifications and get more accurate quotes.

Intermediate. Any compound made and isolated during a synthetic route between the starting materials and the final product. Intermediates are the majority of what a fine chemical supplier sells. They are defined by their position in a route, not by their structure — the same molecule is an intermediate in one process and a final product in another.

Building block. A small, commercially available molecule bearing reactive handles, used as a starting point in library or medicinal chemistry. Building blocks are the currency of discovery chemistry. Our heterocyclic compounds category and fluorinated compounds category collect the two most-used classes; 3-Iodopyridine (CAS 1120-90-7) and 4-Fluoroindole (CAS 387-43-9) are representative examples of each.

Scaffold. The core structural framework of a molecular series, on which substituents vary. Medicinal chemistry programs are usually organized around scaffolds, and sourcing follows: you buy one scaffold and many decorating reagents.

Functional group. The reactive part of a molecule that determines how it behaves and what it can be coupled to. Catalogs are organized by functional group because that is how chemists search: you do not look for a molecule, you look for a molecule with the handle you need. The four workhorse classes a buyer meets constantly are carboxylic acids (amide and ester formation — for example 4-Acetylbenzoic acid (CAS 586-89-0)), amines (the coupling partner for those acids, and the most common basic center in drugs — for example 3-Iodoaniline (CAS 626-01-7)), aldehydes and ketones (reductive amination and condensation chemistry — for example 2,4-Difluorobenzaldehyde (CAS 1550-35-2)), and esters (protected acids and prodrug precursors — for example Methyl-4-iodobenzoate (CAS 619-44-3)). Buyer note: when a supplier cannot offer your exact compound, describing the functional group and the handle position you need often surfaces a workable alternative faster than repeating the CAS number.

Synthon. A conceptual fragment representing a piece of a target molecule and the bond disconnection that would produce it. A retrosynthetic planning term rather than a purchasing term, but it appears in route discussions with chemists.

Reagent. A substance added to bring about a chemical transformation, consumed in the process. Distinct from a solvent (the medium) and a catalyst (not consumed).

Catalyst. A substance that increases reaction rate without being consumed. In pharmaceutical synthesis, transition metal catalysts — palladium, ruthenium, rhodium, nickel — dominate coupling and hydrogenation chemistry, and their residues are the primary reason ICH Q3D exists.

Chiral. Describing a molecule not superimposable on its mirror image, typically because of a stereocenter. Chirality is the single largest source of specification complexity in pharmaceutical sourcing, because the two mirror images can have different biological effects.

Racemic. A 50:50 mixture of two enantiomers, with zero net optical rotation. Racemic material is generally cheaper than single-enantiomer material and is often what a catalog offers by default. Buyer note: check whether a catalog listing is racemic or single-enantiomer before you compare prices. Comparing a racemate to an enantiopure quote is comparing two different products. (S)-2-Methylpyrrolidine (CAS 59335-84-1) is an example of a single-enantiomer building block where the racemate is a distinct commercial item.

Enantiomer. One of a pair of mirror-image stereoisomers. Identical in most physical properties except interaction with other chiral entities, which includes essentially all biological targets and chiral chromatography columns.

Diastereomer. Stereoisomers that are not mirror images, arising when a molecule has two or more stereocenters. Unlike enantiomers, diastereomers differ in ordinary physical properties, which is why they can often be separated by conventional chromatography or crystallization.

Polymorph. A distinct crystalline arrangement of the same molecule. Polymorphs differ in solubility, dissolution rate, stability, melting point and processability. Buyer note: for solid materials, specify the form and require XRPD. A supplier can meet every chemical specification and still ship a form that behaves differently in your process.

Salt form. A compound converted to an ionic salt — hydrochloride, mesylate, tosylate, sodium — to improve stability, solubility or crystallinity. The salt is a different substance with a different molecular weight, which affects the mass you need to buy.

Free base. The neutral, non-salt form of a basic compound. When a supplier quotes an amine, confirm whether the price and the assay refer to the free base or a salt, and whether the assay is stated on a free-base-equivalent basis. 1-BOC-3-aminopiperidine (CAS 184637-48-7) is commonly encountered both as free base and as a salt, and the two are not interchangeable on a molar basis without correction.

Telescoping. Carrying a reaction product forward into the next step without isolating it, usually as a solution. Telescoping saves time, solvent and yield loss, and removes an isolation point where impurities could have been rejected. A common source of the difference between a laboratory route and a manufacturing route.

Work-up. The sequence of operations after a reaction is complete — quench, phase separation, washing, drying, concentration — that prepares the crude product for isolation. Work-ups scale badly and are a frequent cause of surprises between the laboratory and the pilot plant.

Yield versus isolated yield. Yield may be reported by analysis of a reaction mixture; isolated yield is the mass of purified product actually obtained, as a percentage of theory. Only isolated yield predicts what arrives in a drum. Buyer note: when a supplier quotes a route, ask for isolated yields step by step, not overall. An overall yield hides which step is fragile.

Atom economy. The proportion of reactant mass that ends up in the desired product. A green chemistry metric that correlates with waste cost and, at scale, with cost of goods. Our green chemistry discussion covers where it changes decisions.

Scale-up. Moving a process from laboratory to larger equipment. Heat transfer, mixing, addition rate and hold times all change with scale, and a route that works in a flask can fail in a reactor. See scale-up challenges.

Pilot. An intermediate-scale run, typically tens to hundreds of liters, used to prove a process before commercial manufacture and to generate material for late-stage studies.

Kilo lab. A facility scaled between laboratory and pilot plant, typically producing hundreds of grams to a few kilograms. Where most first GMP campaigns and most toxicology supply runs happen.

Campaign. A defined production run of a specified quantity, as opposed to continuous or stock production. Custom synthesis is sold in campaigns, which is why lead times are driven by scheduling as much as by chemistry.

Commercial and Logistics Terms

This vocabulary comes from trade and contracts rather than chemistry, and it is where the largest unbudgeted costs hide.

RFQ (Request for Quotation). The document that starts a sourcing conversation. The quality of an RFQ determines the quality and comparability of the quotes it produces — an incomplete RFQ produces quotes with different assumptions that cannot be compared on price. What to include in a custom synthesis RFQ covers the full checklist.

MOQ (Minimum Order Quantity). The smallest quantity a supplier will sell, driven by setup cost, vessel size and packaging rather than by material cost. MOQ is often negotiable for a first order and rarely negotiable at scale.

Lead time. The elapsed time from purchase order to delivery. Must be read as a sum of parts: raw material procurement, queue time for equipment, synthesis, purification, analysis, release and shipping. Buyer note: ask a supplier to break lead time into those parts. The breakdown tells you what can be expedited and what cannot.

Incoterms. The standardized three-letter trade terms defining who bears which cost and which risk at which point in a shipment. Four appear constantly in chemical purchasing:

Incoterm	Seller bears	Buyer bears	Risk transfers
EXW (Ex Works)	Making the goods available at their premises	Loading, export clearance, freight, insurance, import duty, delivery	At seller’s premises, before loading
FOB (Free On Board)	Delivery to and loading on the vessel, export clearance	Ocean freight, insurance, import duty, inland delivery	When goods are on board the vessel
CIF (Cost, Insurance and Freight)	Freight and minimum insurance to the named port	Import duty, clearance, inland delivery from port	On board at origin, despite seller paying freight
DDP (Delivered Duty Paid)	Everything, including import duty and clearance	Unloading at destination	At the named destination

The trap in CIF is that the seller pays freight while the buyer carries risk from origin. The trap in EXW is that a headline price that looks lowest is the one where you have bought the least. Buyer note: normalize every quote to the same Incoterm before comparing. A DDP quote 15 percent above an EXW quote is frequently the cheaper purchase.

Landed cost. The total cost of getting material to your dock: unit price plus freight, insurance, duty, brokerage, handling and any inspection cost. The only price worth comparing across suppliers in different countries.

Total cost of ownership (TCO). Landed cost plus everything downstream: incoming inspection and testing, rework or rejection cost, inventory carrying cost, qualification cost, and the expected cost of supply failure. TCO is what makes a slightly more expensive qualified domestic source cheaper than a cheap offshore one.

HTS code. The Harmonized Tariff Schedule classification determining the duty rate on an imported good. Chemical classifications are granular and two similar compounds can carry different rates. Buyer note: get the HTS code from the supplier in writing and verify it independently. Misclassification is your liability as importer, not theirs.

Country of origin. The country where the goods were produced or last substantially transformed, which drives duty rate, trade-remedy exposure and, increasingly, customer questions. Not the same as the country you bought from or the country it shipped from.

Duty drawback. A refund of duties paid on imported goods that are subsequently exported, either as-is or incorporated into an exported product. Relevant to anyone importing intermediates and exporting API or drug product. Materially valuable and routinely unclaimed.

FTZ (Foreign Trade Zone). A designated US site treated as outside customs territory for duty purposes. Goods can be stored or processed in an FTZ with duty deferred, reduced or eliminated depending on the outcome. Useful for buffer inventory that may be re-exported.

Force majeure. A contract clause excusing performance when specified extraordinary events occur. Buyer note: read the definition, not the heading. Clauses that include routine supply interruption, raw material shortage or regulatory action give a supplier broad latitude to walk away from a price without consequence.

Price protection. A contractual commitment to hold price for a defined period or within a defined band, sometimes indexed to a published raw material or currency benchmark. The counterweight to a broad force majeure clause.

Safety stock. Inventory held to buffer against demand variability and supply interruption. Fast to establish, weak as a permanent answer, and limited by retest date and carrying cost.

Dual sourcing. Maintaining two qualified suppliers for the same input. More expensive per unit and substantially cheaper on TCO once the expected cost of interruption is priced in.

Qualification. The documented process of establishing that a supplier and its material meet your requirements — documentation review, sample testing against specification, and internal approval. Timelines run 60 to 90 days for a non-GMP intermediate with an established method, and six to eighteen months where a regulatory filing is involved.

Change control. The formal process by which a change to a material, process, supplier or specification is evaluated, approved and documented before implementation. Buyer note: a supplier who changes their route without telling you has breached the most important commitment in a quality agreement. Require written notification of any change to process, site or raw material source.

MSDS / SDS. The Material Safety Data Sheet, now standardized globally as the Safety Data Sheet under GHS, with sixteen defined sections covering hazards, handling, exposure controls, physical properties, toxicology, disposal and transport. Required before material can be received in most facilities.

GHS (Globally Harmonized System). The UN system for classifying and communicating chemical hazards, implemented in the US through OSHA’s Hazard Communication Standard. It defines the pictograms, signal words, hazard statements and SDS format. Errors here delay shipments at the dock — see GHS labeling requirements and common mistakes.

Terms People Use Loosely and Should Not

Six pairs account for most of the expensive misunderstandings in chemical sourcing. Each pair looks like a synonym and is not.

GMP versus GLP

GMP governs how material is manufactured. GLP governs how a non-clinical study is conducted. They are different quality systems, applied to different activities, by different parts of an organization, and neither substitutes for the other.

GMP applies to production: batch records, validated processes, qualified equipment, released raw materials, an independent quality unit, and a batch release decision. GLP applies to safety studies: a study protocol, a study director, raw data integrity, archival, and quality assurance inspection of the study itself. A GLP-compliant toxicology laboratory has no authority to release a GMP batch. A GMP plant running a toxicology study without GLP produces data a regulator may refuse.

What the confusion costs: a buyer asked to supply “GLP material” for a toxicology study is being asked for something that does not exist as a category. Toxicology studies are GLP; the material dosed in them is usually non-GMP, characterized to a defined specification, with a documented certificate of analysis and often a stability statement. Buying GMP material for a study that does not need it can multiply the material cost several times over with no regulatory benefit.

Purity versus assay

Purity says what fraction of the sample is not something else. Assay says how much of the named substance is actually there.

Purity is typically chromatographic — area percent by HPLC or GC. It only sees what elutes and what the detector responds to. Water, inorganic salts, non-chromophoric impurities and residual inorganic reagents are invisible to a UV-detected HPLC purity number. Assay is a quantitative determination against a reference standard, and it counts mass.

A material can honestly be reported as 99.6 area percent pure and assay at 91 percent because it carries 6 percent water and 3 percent residual solvent. Both numbers are correct. They measure different things.

What the confusion costs: you are charged for and stoichiometrically dose against a mass you do not have. On a coupling reaction, a 9 percent assay shortfall on the limiting reagent is a 9 percent yield loss plus an unexpected excess of the other partner. Buyer note: for anything you will use stoichiometrically, put an assay method and limit on the specification, alongside purity, water content and residual solvents. Then check that assay plus water plus solvents plus impurities approximately reconciles to 100 percent. When it does not, ask why.

CRO versus CDMO

A CRO sells knowledge. A CDMO sells manufactured, releasable material made by a process it owns.

The overlap is real — many organizations do both, and a CRO will happily make you a kilogram. The distinction that matters is what the contract is buying. A CRO engagement is scoped in effort and deliverables: a route, a method, a compound set, a report. A CDMO engagement is scoped in material: a quantity, to a specification, released against a quality agreement, repeatable next quarter.

What the confusion costs: engaging a CRO for what is really a manufacturing need produces material with no batch record, no process validation and no path to scale, which then has to be requalified from scratch when the program advances. Engaging a CDMO for what is really a research question produces a rigid, expensive relationship optimized for repeatability when what you needed was iteration. Our CRO versus CDMO decision framework works through the choice.

Intermediate versus API

An intermediate is a compound in the middle of a route. An API is the finished active substance, and it is a regulatory category with obligations attached.

The chemistry can be nearly identical — the penultimate intermediate and the API may differ by a single deprotection or a salt formation. The regulatory difference is total. An API facility is registered and inspected as such. API manufacture requires full ICH Q7 compliance, a defined control strategy, stability data, and appearance in the filing. Intermediate manufacture upstream of the registered starting material can be non-GMP.

What the confusion costs: in both directions. Buyers who describe an intermediate as an API to a supplier receive a quote priced for GMP API manufacture, sometimes several times what the material needs to cost. Buyers who treat an API purchase as an intermediate purchase discover during filing that their supplier holds none of the documentation the submission requires, at which point the qualification restarts with a different vendor and the timeline slips by months.

Distributor versus manufacturer

A manufacturer made the material and holds the batch record. A distributor bought it and resold it.

Distributors add genuine value: they aggregate catalogs, break bulk, hold local stock, and handle small orders that no manufacturer wants. But a distributor cannot tell you how the material was made, cannot change the process, cannot guarantee that next year’s lot comes from the same plant, and cannot produce a batch record they never had. Some distributors reissue a certificate of analysis under their own name, which makes the original manufacturer invisible on the paperwork.

What the confusion costs: the classic failure is qualifying a supplier, running a program on their material for two years, and discovering at scale-up that the qualified supplier was a distributor whose upstream source has changed twice. Everything you validated was validated against material from a plant you never identified. Buyer note: ask directly — do you manufacture this yourself, and at which site? Get the answer in writing, and require notification if the manufacturing site changes.

Potency versus purity

Purity is a chemical measure of what else is in the sample. Potency is a measure of active content, and depending on context it means either biological activity or assay corrected to an active basis.

In small-molecule chemical supply, “potency” usually means the assay expressed on an as-is basis, corrected for water, residual solvent, counterion and salt stoichiometry — the fraction of the shipped mass that is actually the active moiety. A hydrochloride salt of a compound with molecular weight 300 has a free-base potency around 89 percent by mass before any impurity is counted, purely because of the chloride.

In biological and some formulation contexts, potency means measured activity in an assay, which can diverge from chemical content entirely — for instance when a small amount of a highly active impurity or a partially degraded fraction shifts the response.

What the confusion costs: dosing and formulation errors. If you order 100 g of a compound and receive 100 g of its hydrochloride salt, you have roughly 89 g of active on a free-base basis, and a formulation calculated on nominal mass is systematically wrong. Buyer note: state on the specification whether quantities, price and assay refer to the salt form as shipped or to free-base equivalent. Then confirm which basis the supplier’s COA uses. This one line resolves the most common unit-of-measure dispute in the industry.

The pattern behind all six

Each of these pairs shares a structure: a word that means one thing in a chemistry context and another in a regulatory or commercial context, used by two parties who each assume their own reading. The defense is the same in every case — replace the ambiguous word in your specification with the measurement that resolves it. Not “high purity” but “not less than 99.0 area percent by HPLC method X, assay 98.0 to 102.0 percent on the anhydrous basis, water not more than 0.5 percent by Karl Fischer”. Longer to write once. Cheaper than every argument it prevents.

For reference materials where these distinctions are most acute, see our reference standard sourcing guide. For the underlying compendial definitions, the USP general chapters and the NIST standard reference materials program are the primary sources, and the FDA guidance documents database carries the current agency positions cited throughout this glossary.

ChemContract Research has been supplying research and industrial chemistry since 2000, with US-based custom synthesis from milligram to multi-ton, contract R&D for route development, analytical services for characterization and method transfer, and a catalog of more than 7,000 compounds you can browse at our product catalog. If a specification you are about to send out contains any of the ambiguous terms above, send it to us and we will return a marked-up version alongside a quote within 24 hours.

Frequently Asked Questions

What is the difference between a CRO and a CDMO?

A CRO performs research services — route scouting, medicinal chemistry, analytical method development — and delivers knowledge and small quantities of material. A CDMO develops a process and then manufactures material at commercial scale under GMP, delivering registered product. Many organizations do both, but the contract, the quality expectations and the pricing model differ substantially between the two kinds of work.

Is assay the same as purity?

No. Assay is the measured amount of the named substance in the sample, typically by a quantitative method against a reference standard. Purity is the fraction of the sample that is not something else, often reported as chromatographic area percent. A material can be 99.5 area percent pure by HPLC and still assay at 92 percent because it contains 8 percent water or residual solvent that the chromatogram never sees.

What does GMP mean on a chemical quotation?

GMP means the material was made under a documented quality system meeting Good Manufacturing Practice requirements, with batch records, change control, qualified equipment, released raw materials and a quality unit independent of production. For APIs the applicable standard is ICH Q7. GMP is not a purity claim. GMP material and research-grade material can hit identical specifications; the difference is the documented evidence behind them.

What is a registered starting material?

A registered starting material, or RSM, is the point in a synthetic route where GMP requirements begin and where the material is named in a regulatory filing. Steps before the RSM can be run non-GMP; steps from the RSM onward must be GMP. Where the RSM sits is a negotiated regulatory position, and moving it changes both cost and the scope of supplier qualification.

What does DDP mean compared with EXW?

Under EXW, Ex Works, the buyer takes on cost and risk from the seller’s door, including export clearance, freight, insurance, import duty and delivery. Under DDP, Delivered Duty Paid, the seller bears all of it through to the named destination including import duty. EXW quotes look cheapest and are the most expensive to actually execute for a buyer without a freight organization.

What is the difference between a distributor and a manufacturer?

A manufacturer synthesizes the material in a facility it controls and can produce batch records for it. A distributor buys finished material and resells it, sometimes repackaging under its own label. Distributors offer speed and small quantities; manufacturers offer traceability, process control and the ability to make more when demand grows. Ask which one you are talking to before you qualify a supply chain.